Inovio Pharmaceuticals (INO) Q1 2025 earnings summary

Executive summary

• On track to begin rolling BLA submission for INO-3107 for recurrent respiratory papillomatosis in mid-2025, with completion and FDA acceptance targeted by year-end 2025 and potential approval in mid-2026 if granted priority review.

• Manufacturing issues with the CELLECTRA device resolved; device design verification testing underway and expected to complete in 1H25 for regulatory submissions.

• Published positive Phase 1/2 clinical and immunological results for INO-3107, showing new T cell populations and reduced need for surgery; longer-term data submitted for peer review.

• Announced promising interim results from Phase 1 trial of DNA-encoded monoclonal antibodies (DMAbs), with durable in vivo antibody production and no anti-drug antibodies detected.

• Pipeline includes INO-3112 for oropharyngeal cancer (Phase 3 trial planned), INO-5401 for glioblastoma, and other DNA medicine candidates; no product revenue to date.

Financial highlights

• Operating expenses decreased 20% year-over-year to $25.1 million in Q1 2025 from $31.5 million in Q1 2024.

• Net loss for Q1 2025 was $19.7 million ($0.51 per share), improved from $30.5 million ($1.31 per share) in Q1 2024.

• Cash, cash equivalents, and short-term investments totaled $68.4 million at March 31, 2025, down from $94.1 million at year-end 2024, with a projected cash runway into Q1 2026.

• Revenue was $65,000 for Q1 2025, up from $0 in Q1 2024, all from a collaborative arrangement with ApolloBio.

• Research and development expenses decreased 23% year-over-year to $16.1 million, mainly due to lower drug manufacturing, contract labor, and stock-based compensation.

Outlook and guidance

• Cash and investments expected to support operations into Q1 2026; additional financing will be required to complete development and commercialization of INO-3107 and other candidates.

• Management believes there is substantial doubt about the ability to continue as a going concern beyond Q1 2026 without new capital.

• BLA rolling submission for INO-3107 to begin mid-2025, with FDA acceptance targeted by year-end and potential PDUFA date in mid-2026 if priority review is granted.

• Confirmatory trial for INO-3107 to launch at over 20 major U.S. medical centers.

• Commercial launch preparations underway, including market research and commercial organization build-out; U.S. commercialization to be handled internally, with ex-U.S. partnerships considered.